Among Sensex firms, Bajaj Finserv, Bajaj Finance, Tata Steel, Reliance Industries, Sun Pharma, Tata Motors Passenger Vehicles, Axis Bank and Infosys were among the major gainers. Bharti Airtel and Asian Paints emerged as the laggards from the pack.
After falling 17 per cent since the start of the year to its March lows, the stock of the country's largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries, has clawed back nearly half of those losses. Recent acquisitions, a favourable court ruling in the case of the hair loss drug Leqselvi, an edge over peers owing to its specialty portfolio, and a diversified global presence have supported the recovery.
Indian pharmaceutical companies are stepping up their efforts to combat the problem of counterfeit drugs, employing a variety of strategies, from packaging innovations to engaging private investigation agencies. The stakes are high, as counterfeit medicines not only harm consumers but also tarnish the reputation of leading brands.
The platform has seen a growth of 70% in watch time for South content, which is more than the national average.The South has outperformed the rest of India in subscription depth, retention and connected TV adoption.
From the Sensex firms, Adani Ports, NTPC, Power Grid, HCL Tech, Tata Steel, Sun Pharma, Trent and Asian Paints were among the major gainers. However, Bharat Electronics, Eternal, Mahindra & Mahindra and Maruti were among the laggards.
From the Sensex pack, Asian Paints, Tech Mahindra, Tata Consultancy Services, Bajaj Finserv, Adani Ports, HCL Technologies, Bharti Airtel, Infosys, Trent, Reliance Industries, UltraTech Cement, Sun Pharmaceuticals, Eternal, Titan and Bajaj Finance were the gainers. On the other hand, Tata Steel, Tata Motors Passenger Vehicles, Tata Motors Commercial Vehicles, Bharat Electronics, Kotak Mahindra Bank and PowerGrid were the laggards.
'Indian markets may underperform global peers for the next two quarters.' 'But beyond that, India should catch up and resume its long-term growth path.'
So far this year, the rupee has fallen by 4.2 per cent, the worst among its Asian peers.
The Rajasthan government has suspended the state drug controller and halted the distribution of medicines manufactured by Kaysons Pharma following reports of children's deaths allegedly linked to contaminated cough syrup.
When Chennai-based Wedding Designer Ambika Gupta first received a brief for a destination wedding in Udaipur, she had no idea it would turn into one of the most high-profile celebrations of the season.
Prime Minister Narendra Modi will host Russian President Vladimir Putin for a private dinner and summit, focusing on defence, trade, and geopolitical issues, including the Ukraine conflict and the impact of US sanctions.
Russian President Vladimir Putin arrived in New Delhi for a two-day visit focused on strengthening ties with India, including defense cooperation and trade, amidst a changing geopolitical landscape.
Investors who constantly hop between 'top-performing' funds often end up earning far lower returns than the very funds they invest in -- simply because they enter late and exit early. Best investors don't chase returns, they chase discipline, says Ramalingam Kalirajan.
Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company, which had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, said its managing director & global CEO, Umang Vohra, has decided not to seek re-appointment upon completion of his current term on March 31, 2026, Cipla Ltd said in a regulatory filing.
Among Sensex firms, Tata Motors, Mahindra & Mahindra, Bharat Electronics, UltraTech Cement, Trent, Sun Pharma, Power Grid and Reliance Industries were the major laggards. However, Titan, Infosys, Tata Consultancy Services, HCL Tech and Tech Mahindra were among the biggest gainers.
Tata Sons, now debt-free, has asked the RBI to drop its 'upper-layer NBFC' tag and allow it to stay private.
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.
After a year of modest returns, equity investors may anticipate gains of 10-15 per cent in Samvat 2082, which began on October 21. Although valuations have moderated from their peaks a year earlier, they remain above long-term averages, potentially limiting sharp upsides.
Among Sensex firms, Hindustan Unilever dropped the most by 3.20 per cent. UltraTech Cement, Kotak Mahindra Bank, Adani Ports, Titan, HDFC Bank and Axis Bank were also among the laggards. However, Bharti Airtel, ICICI Bank, Bharat Electronics and Sun Pharma were among the gainers.
The Maharashtra Food and Drug Administration (FDA) on Monday appealed to the people to immediately stop the sale or use of a specific batch of Coldrif syrup, following child deaths in Madhya Pradesh and Rajasthan allegedly linked to the medicine.
Around six weeks ago, Sun Pharmaceutical Industries, India's largest drugmaker, suffered a setback, which led to a selloff in the share. The US District Court of New Jersey granted Incyte's request for a preliminary injunction against Sun Pharma's launch of Leqselvi, a drug that treats alopecia.
The death toll from contaminated cough syrup in Madhya Pradesh has risen to 22, with two more children succumbing to kidney infections. An investigation is underway, and arrests have been made.
With several $500 million-plus deals in the pipeline -- including ICICI Prudential AMC, Lenskart, PhonePe, Groww, PhysicsWallah, Meesho, Pine Labs, and Zepto -- investment bankers look poised for another year of hefty bonuses in 2025.
Among Sensex firms, NTPC, Axis Bank, Power Grid, Bharti Airtel, Eternal and Sun Pharma were the major gainers. However, Infosys, Titan, UltraTech Cement and Hindustan Unilever were among the laggards.
Among Sensex firms, Maruti, Axis Bank, Larsen & Toubro, ICICI Bank, Bharti Airtel, Infosys, Adani Ports and Hindustan Unilever were the laggards. However, Titan, State Bank of India, Eternal and Trent were among the major gainers.
Among Sensex firms, HCL Tech, ICICI Bank, Titan, Trent, Kotak Mahindra Bank, Hindustan Unilever, Mahindra & Mahindra and HDFC Bank were the major laggards. However, Adani Ports, Bharti Airtel, SBI, NTPC and Sun Pharma were among the gainers.
The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
Ahead of the key meeting called by the steel ministry with the industry captains on Monday to discuss the impact of rising steel imports, companies have raised the issue of cheaper 'substandard' inflows from China, Vietnam, and South Korea, saying they are setting the benchmark for domestic prices and squeezing the profitability of Indian producers.
Among Sensex firms, Eternal, Sun Pharma, Infosys, HDFC Bank, HCL Tech, Hindustan Unilever, Power Grid, ITC and Adani Ports were the major gainers. However, Tata Motors, Trent, Bajaj Finance and Asian Paints were among the laggards.
The Enforcement Directorate (ED) raided premises linked to Sresan Pharmaceuticals, the manufacturer of Coldrif cough syrup linked to the deaths of children in Madhya Pradesh and Rajasthan, and top officials of the Tamil Nadu FDA as part of a money laundering investigation.
A Russian missile struck a warehouse belonging to an Indian pharmaceutical company, Kusum, in Ukraine, according to the Ukrainian embassy in India. The embassy alleged that Russia, despite claiming a "special friendship" with India, deliberately targeted Indian businesses in Ukraine. The strike reportedly destroyed medicines intended for children and the elderly. This incident follows a similar attack on a major pharmaceuticals warehouse in Kyiv, which was destroyed by Russian drones, as reported by the UK's ambassador to Ukraine. Kusum Healthcare, the company whose warehouse was hit, has a presence in 29 countries, including Ukraine. This attack comes amidst ongoing tensions in the region as Russia continues its offensive against Ukraine, despite US efforts to push for a ceasefire. Ukrainian Foreign Minister Andrii Sybiha accused Russia of being the sole obstacle to peace and claimed that Moscow rejected a US-brokered proposal for a ceasefire.
Among Sensex firms, Tata Steel, HCL Tech, UltraTech Cement, Bharat Electronics, Sun Pharma and Tata Consultancy Services were the major gainers. However, Axis Bank, Titan, Maruti and Tata Motors were among the laggards.
The WHO will take a call on issuing a 'Global Medical Products Alert' on the cough syrup, Coldrif, after receiving an official confirmation from authorities here. The agency issues such alerts for substandard and contaminated medicines.
United States President Donald Trump has named 23 countries as the major drug transit or major illicit drug-producing countries in a 'Presidential Determination' submitted to Congress.
'India needs at least 70,000 to 80,000 eyewear stores; our 2,000 stores are just a drop in the ocean.'
India's drug regulator CDSCO has recalled three cough syrups and halted their production after the WHO raised concerns about potential contamination and links to child deaths. The WHO is investigating reports of pediatric illnesses and deaths in India potentially linked to contaminated syrups.
A generic cough syrup supplied to the Rajasthan government has been linked to the deaths of two children and others falling sick in the state, prompting authorities to ban 22 batches of the drug and order an inquiry.
Stock markets will be driven by RBI's interest rate decision, tariff-related developments, global trends and trading activity of foreign investors in this holiday-shortened week, analysts said.
The World Health Organisation (WHO) has issued an alert against three "substandard" oral cough syrups identified in India and urged national regulatory authorities worldwide to immediately notify it if these are detected in their country.
New Delhi-based pharmaceutical major Mankind Pharma is poised to take pole position in women's health portfolio in the India Pharma Market (IPM) after completing the Rs 13,630 crore deal to acquire Bharat Serums and Vaccines (BSV), senior company officials said. The deal potentially opens doors for Mankind Pharma to the overseas markets, which currently draws 92 per cent of its revenues from India. The combined entity will draw around 13 per cent revenues from the international market, with the remaining coming from the domestic market.
